What is the appropriate initiation regimen and monitoring plan for brexpiprazole (Rexulti) to treat agitation and behavioral symptoms in an Alzheimer’s disease patient?

Rexulti (Brexpiprazole) Initiation for Alzheimer's Agitation

Start brexpiprazole at 0.5 mg once daily and titrate to a target dose of 2 mg daily over 1-2 weeks, with a maximum of 3 mg daily if needed, but only after exhausting nonpharmacological interventions and confirming severe, dangerous, or significantly distressing symptoms. 1

Pre-Initiation Requirements

Before starting brexpiprazole, you must complete several critical steps per APA guidelines:

• Assess symptom severity: Document the type, frequency, severity, pattern, and timing of agitation using a quantitative measure (e.g., Cohen-Mansfield Agitation Inventory) 2
• Rule out modifiable causes: Evaluate for pain, infection, medication side effects, environmental triggers, or other treatable contributors to agitation 2
• Confirm indication threshold: Only initiate if symptoms are severe, dangerous, and/or cause significant patient distress 2
• Trial nonpharmacological interventions first: Review the clinical response to person-centered behavioral approaches before prescribing antipsychotics 2
• Obtain informed consent: Discuss risks (including increased mortality in elderly dementia patients) and benefits with the patient (if feasible) and surrogate decision-maker 2, 1

Critical caveat: The FDA black box warning states that elderly patients with dementia-related psychosis treated with antipsychotics have increased risk of death. Brexpiprazole carries this warning despite its approval for agitation in Alzheimer's disease 1.

Dosing Algorithm

Standard Initiation Schedule

Week 1: Start 0.5 mg once daily 1

Week 2: Increase to 1 mg once daily

Week 3-4: Titrate to target dose of 2 mg once daily 1

• The 2 mg dose demonstrated statistically significant improvement in agitation (CMAI score reduction of approximately 5 points greater than placebo at 12 weeks) 3, 4
• If inadequate response at 2 mg after 2-4 weeks, may increase to 3 mg daily (maximum dose) 1

Administer once daily with or without food 1

Dose Adjustments for Special Populations

Renal impairment (CrCl <60 mL/min): Maximum 2 mg daily 1

Hepatic impairment (moderate to severe): Maximum 2 mg daily 1

CYP2D6 poor metabolizers: Reduce dose by 50% 1

Drug interactions:

• Strong CYP2D6 inhibitors (paroxetine, fluoxetine): No adjustment needed for this indication 1
• Strong CYP3A4 inhibitors: Reduce brexpiprazole dose by 50%
• Strong CYP3A4 inducers: Double the brexpiprazole dose

Monitoring Plan

Baseline Assessment

• Vital signs (blood pressure, heart rate) - assess for orthostatic hypotension risk 1
• Weight and BMI
• Fasting glucose and lipid panel
• Complete blood count if history of leukopenia/neutropenia 2
• Cognitive function (MMSE or similar)
• Extrapyramidal symptoms assessment (SAS, BARS, AIMS) 1
• Quantitative agitation measure (CMAI or NPI-NH) 2

Ongoing Monitoring

Weeks 1-4 (titration phase):

• Weekly assessment of agitation symptoms using quantitative measure 2
• Monitor for adverse effects: dizziness, headache, nasopharyngitis, somnolence, urinary tract infections 1
• Check vital signs at each visit for orthostatic hypotension 1

Week 4 decision point:

• If no clinically significant response after 4 weeks at adequate dose: taper and discontinue 2
• If partial response: consider increasing to 3 mg daily if not already at maximum dose

Weeks 4-12:

• Assess agitation every 2-4 weeks with quantitative measure
• Monitor weight monthly (mean weight increase in trials was modest but present) 1
• Assess for extrapyramidal symptoms monthly 1
• Screen for sedation/somnolence (reported in 3.7% vs 1.8% placebo) 1

After 12 weeks (if positive response):

• Discuss continuation vs. tapering with patient/surrogate decision-maker 2
• Review initial goals, observed benefits, side effects, and risks of continued exposure 2
• Consider periodic taper attempts, as symptoms may improve over time

Safety Considerations

Common Adverse Events

The most frequent adverse events (≥4% and greater than placebo) in Alzheimer's agitation trials were 1:

• Nasopharyngitis (4%)
• Dizziness (5%)
• Headache (9%)
• Somnolence (3%)
• Urinary tract infections (3%)

Notably, brexpiprazole was generally well-tolerated with discontinuation rates similar to placebo (5.6% vs 4.8%) 1, 5

Serious Safety Concerns

Cerebrovascular events: Increased risk of stroke/TIA in elderly dementia patients 1

Extrapyramidal symptoms: Incidence of EPS-related adverse events was 5.3% vs 3.1% for placebo 1. Monitor with objective scales (SAS, BARS, AIMS)

Metabolic effects: Monitor for hyperglycemia, dyslipidemia, and weight gain, though changes were minimal in trials 1, 5

Mortality: Six deaths (0.9%) occurred in brexpiprazole groups vs one (0.3%) in placebo over 12 weeks, though none were considered treatment-related 5

Cognitive function: No worsening of cognition was observed in trials 5

Clinical Evidence Summary

The approval of brexpiprazole is based on robust evidence from multiple Phase 3 trials. The most recent and highest quality study 3 demonstrated that brexpiprazole 2-3 mg significantly improved agitation (CMAI reduction of -5.32 points vs placebo, p=0.003, Cohen's d=0.35) over 12 weeks in 345 patients. A pooled analysis of 621 participants 4 confirmed these findings with a -4.50 point difference (p<0.001).

Important nuance: While statistically significant, the clinical meaningfulness of a 4-5 point CMAI reduction has been debated 6. However, this represents the first FDA-approved pharmacologic agent specifically for this indication, and the effect size is comparable to or better than other antipsychotics used off-label.

Recent data 7 from Japanese patients confirmed efficacy at both 1 mg and 2 mg doses, though the 2 mg dose showed greater effect. Long-term safety data up to 24 weeks 5 demonstrated continued tolerability without new safety signals.

Common Pitfalls to Avoid

1. Using brexpiprazole "as needed" (PRN): This is explicitly contraindicated - it is a maintenance medication requiring daily dosing 1, 6

2. Skipping nonpharmacological interventions: APA guidelines mandate attempting behavioral approaches first unless emergency situation 2

3. Continuing indefinitely without reassessment: Must evaluate for taper after positive response, as continued antipsychotic exposure carries risks 2

4. Inadequate trial duration: Give at least 4 weeks at therapeutic dose before declaring treatment failure 2

5. Ignoring drug interactions: Brexpiprazole is metabolized by CYP2D6 and CYP3A4 - adjust for inhibitors/inducers 1

6. Not monitoring for falls: Dizziness occurred in 5% of patients; assess fall risk and implement precautions 1